The cumulative evidence of apoptosis induction and increased susceptibility in the R273H p53 mutant raises the possibility that proteasome inhibitors could be used to therapeutically target this subset of NSCLC. The gene discussed is TP53; the disease is non-small cell lung carcinoma.